Dexmedetomidine Versus Dexamethasone as Adjuncts in Erector Spinae Plane Block in Modified Radical Mastectomy
NCT ID: NCT05447949
Last Updated: 2022-07-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2020-12-15
2022-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analgesic Efficacy of Dexmedetomidine as Adjuvant to Levobupivacaine in Ultrasound-guided Erector Spinae Plan Block for Modified Radical Mastectomy
NCT04732377
Analgesic Efficacy of Ultrasound Guided Erector Spinae Block for Modified Radical Mastectomy
NCT04732364
Serratus Anterior Plane Block Versus Erector Spinae Plane Block With Dexmedetomidine Added to Bupivacaine for Ultrasound-Guided Pain Management After Mastectomy
NCT06737458
Ultrasound-guided Multilevel Erectorspinae Plane Block Versus Thoracic Epidural Analgesia for Prevention of Post Mastectomy Pain Syndrome for Breast Cancer Patients
NCT06884852
Effectiveness of Ultrasound Guided Erector Spinae Plane Block Against Ultrasound Guided Serratus Anterior Block in Modified Radical Mastectomy
NCT04606147
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Postoperative pain is usually managed by opioids, yet it is usually associated with side effects including; prolonged sedation, increase in the incidence of recurrence, respiratory depression , nausea , vomiting and ileus. In an attempt to reduce these side effects, thoracic epidural analgesia and paravertebral block became the gold standard regional techniques for breast surgery. However, both techniques may be associated with serious complications such as pneumothorax, spinal cord injury, incompatibility with pre-existing anticoagulation or antiplatelet therapy and hemodynamic instability. Multiple different regional techniques have been developed in the last decade for postoperative pain management of MRM including including erector spinae plane block (ESPB) aiming to be effective and associated with less complications when compared to the gold standard techniques .
ESPB is a simple and safe paraspinal fascial plane block that involves injection of local anesthetic deep in the erector spinae muscle and superficial to the tips of the thoracic transverse processes hoping to block both ventral and dorsal rami of spinal nerves in the paravertebral area. However, regional blocks after a single dose of local anesthetic are of limited duration and efficacy. Hence, the co-administration of adjuvants with local anesthetics may be helpful for prolongation and potentiation of the analgesic effect. Dexmedetomidine is a potent α2agonist of which α2/α1 selectivity is 8 times greater than clonidine and is now emerging as an adjunct to regional and general anesthesia. It can prolong the duration of the nerve block when used with a local anesthetic .Dexamethasone is considered as an adjuvant as it act by reducing the release of inflammatory mediators and by inhibiting discharge of C-fibers. There is a limited number of studies covering the effect of dexmedetomidine versus dexamethasone when added to ESPB, yet they are still lacking in breast surgeries. Our study aims at studying the effect of adding dexmedetomidine compared to dexamethasone as adjuncts to ESPB in modified radical mastectomy.
Objectives:
To identify the intraoperative and postoperative opioid consumption, as well as duration of analgesia and study the effect on hemodynamics.
Hypothesis We hypothesize that the addition of dexmedetomidine to levobupivacaine in US guided ESPB in patients undergoing MRM is superior to either adding dexamethasone to levobupivacaine, or using levobupivacaine alone.
Ethical Considerations The trial will be conducted after approval of departmental and institutional research ethics committee. A written informed consent will be obtained from all participants.
A comparative double-blinded study.
Study setting and location The study will be conducted in the breast operating theatre at National Cancer Institute hospital.
Study population 90 Female patients ASA II,III scheduled for modified radical mastectomy under general anaesthesia.
A. preoperative:
Patient's assessment; History, physical exam, laboratory and radiological investigations at preoperative assessment clinic National Cancer Institute Cairo University. Preoperative assessment on the night of surgery. Patients will be instructed on how to report pain by means of Numeric Pain Rating Scale, in which 0 = "no pain" and 10 = "worst possible pain". An informed consent will be obtained. Preoperative fasting; minimum of 6 hours for food and minimum of 2 hours for water and clear fluids.20G IV cannula is inserted. All patients will be pre-medicated with IV midazolam 0.01-0.02 mg\\kg 30 minutes preoperatively. ESPB with either adjuncts or none at all will be done preoperatively with the patients in a lateral position. After allocation of patients to each study group, patients in group 1 will receive dexmedetomidine with levobupivacaine in ESPB, while patients in group 2 will receive dexamethasone with levobupivacaine in ESPB, \& patients in group 3 will receive levobupivacaine without adjuncts in ESPB.
Technique of ESPB: The block level will be at T5 with the patient in a lateral position. The ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. If the transducer is too lateral, the ribs will be visualized instead; these are recognizable as rounded acoustic shadows with an intervening hyperechoic pleural line. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which the following layers will be visible superficial to the acoustic shadows of the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle and T5 transverse process. A skin wheel using 3 ml of lidocaine 1% is made 2-3 cm above the upper aspect of the transducer, then an echogenic block needle will be inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1 ml glucose 5% and seeing the fluid lifting the erector spinae muscle off the transverse process without distending the muscle. After aspiration; to avoid intravascular injection, 30 ml levobupivacaine 0.25% to which dexmedetomidine (1microgram\\kg) is added in the first group , while dexamethasone (10 mg) is added to levobupivacaine in the second group, and no adjuncts to levobupivacaine is added to the third group. Upon injection, separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used. Fujifilm Sonosite M-Turbo Ultrasound system will be used.
B. Intraoperative:
All patients will be monitored continuously using electrocardiography, non-invasive blood pressure, peripheral oxygen saturation and end tidal carbon dioxide throughout the duration of the surgical procedure. Induction of general anesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated by using 0.5 mg/kg IV of atracurium. Anesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of atracurium o.1 mg\\kg will be provided every 30 minutes. Paracetamol 500 mg and IV ketorolac 30mg will be provided as a part of multimodal analgesia. Rescue analgesia of fentanyl 1 μg/kg will be given if the mean arterial blood pressure or heart rate rises above 20% of the baseline levels. Ringer acetate will be infused to replace the fluid deficit, maintenance and losses, and patients will be mechanically ventilated at an appropriate setting keeping the end-tidal CO2 at 30- 35 mmHg. The first reading of mean arterial pressure (MAP) and heart rate (HR) will be taken before induction of general anesthesia to be defined as a baseline reading, another reading will be taken immediately before surgical incision and at 30-minute intervals intraoperatively. The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg). Extubation will be performed after complete recovery of the airway reflexes.
C. postoperative:
Patients will be transferred to the post-anesthesia care unit (PACU) where the Numeric Pain Rating Scale score, MAP and heart rate will be noted immediately on arrival, then observed for 2 hours \& discharged to the ward afterwards. Rescue analgesia will be provided in the form of IV morphine 3 mg boluses if the patient indicates Numeric Pain Rating Scale ≥ 4. The total amount of morphine given in 24 hours will be recorded for the three groups. A maximum dose of 0.5 mg/kg/24hours of morphine is allowed. IV paracetamol 500 mg \\6 hours and IV ketorolac 30mg\\8 hours will be given as a part of multimodal analgesia. Numeric Pain Rating Scale score, MAP and heart rate will be noted at 4, 8, 12, 16, 20 and 24 hours postoperatively. Side effects such as nausea, vomiting, sedation, respiratory depression (respiratory rate \<10/minute) will be recorded. Postoperative nausea and vomiting (PONV), will be rated on a four-point verbal scale; (none =no nausea, mild =nausea but no vomiting, moderate=vomiting one attack, severe =vomiting \>one attack). 0.1 mg/kg of IV ondansetron will be given to patients with moderate or severe postoperative nausea and vomiting . Sedation will be assessed in the PACU with Ramsay scores.(1 = anxious or restless or both; 2 = cooperative, orientated, and tranquil; 3= responding to commands; 4 = brisk response to stimulus; 5 = sluggish response to stimulus; and 6 = no response to stimulus). A Ramsay score of 5 or 6 will be considered excessively high sedation levels; a Ramsay score of 2 to 4 will be considered adequate sedation levels needing observation; a Ramsay score of 1 will be considered inadequate or insufficient sedation levels .
Sample size As there was no study reporting results on a similar hypothesis, sample size was calculated based on the results of pilot study;SPSS version 23.0 was used to generate a list of 20 subjects who were randomly assigned into two groups each of 10 for the following treatment A) ESPB + Dexamethasone B) ESPB + Precedex Assuming a pooled standard deviation of 2.37 units, the study would require a sample size of thirty for each group (i.e. a total sample size of 60, assuming equal group sizes), to achieve a power of 90% and a level of significance of 1% (two sided), for detecting a true difference in means of post operative morphia consumption between ESPB + Dexamethasone and ESPB + Precedex groups of -2.4 (i.e. 2.4 - 4.8) units.
Statistical analysis PSS version 27.0 will be used in data analysis. Quantitative variables were tested for normality to select appropriate statistical tests. Mean and standard deviation described quantitative data with median and range. Comparison of means (or medians) of two independent groups will be done using t test. To show the effect of time on vitals, parametric repeated measures ANOVA or Friedman test will be used to show changes overtime both intra and post-operative. Post-hoc test will be used for pairwise comparisons and will be Tucky adjusted. Chi-square and Fisher Exact were used for testing proportion independence. P value was always two tailed and set significant at 0.05 level
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (ESPB + Dexmedetomidine)
Patients received Ultrasound guided ESPB with addition of dexmedetomidine 1 Mcg/kg to 30 ml levobupivacaine 0.25%, N=30 (16)
Adjuncts to levobupivacaine in Erector Spinae Plane Block
The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
Group 2 (ESPB+ dexamethasone)
Patients received Ultrasound guided ESPB with addition of dexamethasone 10 mg to 30 ml levobupivacaine 0.25%, N=30 (16)
Adjuncts to levobupivacaine in Erector Spinae Plane Block
The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
Group 3 (ESPB)
Patients received Ultrasound guided ESPB with 30 ml levobupivacaine 0.25%, N=30
Adjuncts to levobupivacaine in Erector Spinae Plane Block
The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Adjuncts to levobupivacaine in Erector Spinae Plane Block
The block level will be at T5 with the patient in a sitting position and full aseptic precautions. T5 transverse process; these are recognizable as flat, squared-off acoustic shadows with only a very faint image of the pleura visible. In a longitudinal US view, in which the following layers will be visible superficial to the transverse processes: skin, subcutaneous tissue, trapezius, erector spinae muscle . Skin is topicalized, then echogenic block needle inserted in plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. After aspiration; to avoid intravascular injection, 30 ml of injectate is injected and separation will be seen. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used (18-19).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physical status ASA II, III.
* Age ≥ 18 and ≤ 65 Years.
* Body mass index (BMI): \> 20 kg/m2 and \< 35 kg/m2.
Exclusion Criteria
* Age \<18 years or \>65 years
* BMI \<20 kg/m2 and \>35 kg/m2
* Known sensitivity or contraindication to drug used in the study (local anaesthetics, opioids).
* History of psychological disorders and/or chronic pain.
* Contraindication to regional anaesthesia e.g. local sepsis, pre- existing peripheral neuropathies and coagulopathy.
* Severe respiratory or cardiac disorders.
* Advanced liver or kidney disease. Pregnancy.
* Physical status ASA IV.
18 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute, Egypt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammed Magdy Abdelrahman Elsayed
Assistant Lecturer of Anesthesiology , ICU and Pain Management
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ashgan R Ali, Professor
Role: STUDY_CHAIR
Anaesthesiology Faculty of Medicine - Cairo University
Heba I Ahmed, Ass. Professor
Role: STUDY_DIRECTOR
Anaesthesiology Faculty of Medicine - Cairo University
Reham M Gamal, Lecturer
Role: STUDY_DIRECTOR
Anaesthesiology National Cancer Institute - Cairo University
Mohammed M Abdelrahman, Ass. Lecturer
Role: STUDY_DIRECTOR
Anaesthesiology National Cancer Institute - Cairo University
Norhan H El Emam, Resident
Role: PRINCIPAL_INVESTIGATOR
Anaesthesiology National Cancer Institute - Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Cancer Institute - Cairo University
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-536-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.